Researchers at the National Institutes of Health (NIH) have determined that dermatitis resulting from topical steroid ...

US-based biopharmaceutical company Biofrontera has finished enrolling subjects in its multicentre Phase III trial of Ameluz ...

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

NIH researchers define diagnostic criteria for topical steroid withdrawal (TSW), distinguishing it from eczema.

The topical treatment had no significant effect on total or central corneal fluorescence staining score.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the successful ...

Opens in a new tab or window ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of starting topical ruxolitinib (Opzelura ...

MIRA Pharmaceuticals unveils Ketamir-2 topical for neuropathic pain, complementing its oral version. Clinical and preclinical ...